Company Overview of Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc., a biotechnology company, develops orally stable peptide therapeutics for drugs against inflammatory bowel diseases (IBD), irritable bowel syndrome disease related targets, and gastrointestinal diseases and disorders. The company offers IL-6, a peptide antagonist as anti-inflammatory agent; and novel hepcidin peptide mimetic for the treatment of iron overload related disorders. Its pipeline includes PTG-100, an a4ß7 integrin specific oral peptide antagonist for the treatment of IBDs; and IL-23, a receptor oral peptide antagonist for treatment of IBDs. Protagonist Therapeutics, Inc. was founded in 2001 and is headquartered in Milpitas, California with discovery ...
521 Cottonwood Drive
Milpitas, CA 95035-7404
Founded in 2001
Key Executives for Protagonist Therapeutics, Inc.
Chief Executive Officer, President and Director
Founder and Vice President of Technology & Alliances
Senior Vice President of Corporate Development
Senior Director of Chemistry
Compensation as of Fiscal Year 2015.
Protagonist Therapeutics, Inc. Key Developments
Protagonist Therapeutics, Inc. Receives SBIR Funding for Oral II-23 Receptor Antagonists for Treatment of Inflammatory Bowel Diseases
Sep 23 15
Protagonist Therapeutics, Inc. announced receipt of a phase 1 Small Business Innovation Research (SBIR) Grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. This award, Number R43DK104445, will support research aimed at optimizing lead molecules in Protagonist's second pipeline program, focused on orally stable peptide antagonists of the interleukin-23 (IL-23) receptor as potential treatments for inflammatory bowel diseases (IBD). Protagonist's research has shown that orally stable, GI-restricted drugs discovered using the company's peptide technology platform is efficacious in rodent models of colitis. This award furthers the company's efforts to translate these proof-of-concept early research findings into a potential human therapeutic that is orally delivered at high drug levels in diseased intestinal tissue with very limited drug concentrations in systemic circulation.
Protagonist Therapeutics, Inc. Presents at BIO-Europe 2015, Nov-03-2015 10:45 AM
Sep 21 15
Protagonist Therapeutics, Inc. Presents at BIO-Europe 2015, Nov-03-2015 10:45 AM. Venue: Munich, Germany.
Protagonist Therapeutics Names Richard S. Shames, M.D. as Chief Medical Officer
Sep 10 15
Protagonist Therapeutics, Inc. announced the appointment of Richard S. Shames, M.D. as Chief Medical Officer. Dr. Shames, most recently Senior Vice President and CMO at Aldea Pharmaceuticals, joins Protagonist with over 25 years of experience in clinical medicine and the biotechnology/pharmaceutical industry.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 10, 2015